Emergent BioSolutions to Webcast Presentations at Upcoming Investor Conferences
More News related to EBS
- Former U.K. Health Protection Agency Director Rejoins Emergent BioSolutions to Head Biodefense Business
- Emergent BioSolutions to Webcast Presentations at Upcoming Investor Conferences
- Emergent BioSolutions (EBS) Acquires MdBio Foundation Facility and Land for $8.2M
- Emergent BioSolutions Enhances Manufacturing Infrastructure with Strategic Acquisition in Baltimore
- Emergent Biosolutions (EBS) Misses Q3 EPS by 4c, Reaffirms
More News related to Press Releases
- CT Red Cross Disaster Exercise Demonstrates First of Its Kind Regional Communications Interoperability
- SmartFurniture.com Design on Demand Platform Now Features the Setu Chair by Herman Miller
- Launch of Flow Diverting Devices in the US Will Slow Growth of Intracranial Aneurysm Coiling Procedures
- GreenVolts Lands Industry Veteran as Senior Vice President of Operations
- Cognex Enters Supply Agreement with German Automaker
ROCKVILLE, Md.--(BUSINESS WIRE)-- Emergent BioSolutions Inc. (NYSE: EBS) announced today that the company will be webcasting its presentation at the following investor conferences during the month of November 2009.
-- The Southwest Ideas Conference
Dallas, TX.
November 11, 2009
Presentation Time: 11:30 AM Central
-- The 6th Annual Lazard Capital Markets Healthcare Conference
New York, NY.
November 17, 2009
Presentation Time: 8:55 AM Eastern
During each presentation, a member of the company's senior management team will provide a corporate overview, including a discussion of product development programs, corporate activities and financial performance.
A webcast of these presentations will be available both live and by replay, accessible from the company's website www.emergentbiosolutions.com under "Investors".
About Emergent BioSolutions Inc.
Emergent BioSolutions Inc. is a biopharmaceutical company focused on the development, manufacture and commercialization of vaccines and therapeutics that assist the body's immune system to prevent or treat disease. Emergent's marketed product, BioThrax(R) (Anthrax Vaccine Adsorbed), is the only vaccine licensed by the U.S. Food and Drug Administration for the prevention of anthrax disease. Emergent's development pipeline includes programs focused on anthrax, botulism, tuberculosis, typhoid, hepatitis B and chlamydia. Additional information may be found at www.emergentbiosolutions.com.
Source: Emergent BioSolutions Inc.
Related Categories
Press ReleasesStocks Mentioned
+0.00Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
